Comments on: Schering-Plough as a turnaround candidate? Unlikely. http://onthepharm.net/2006/06/schering-ploug-turnaround.html Life on the pharm Fri, 21 Nov 2008 18:13:31 +0000 http://wordpress.org/?v=2.6.3 By: Dr.mustafa Shamek http://onthepharm.net/2006/06/schering-ploug-turnaround.html#comment-24128 Dr.mustafa Shamek Wed, 07 Mar 2007 10:32:25 +0000 http://onthepharm.net/2006/06/schering-ploug-turnaround/#comment-24128 To whom it may concern We are a distributer of drugs & medical supplies, working in one of the main hospitals here in Libya. After the huge expansion in the marketing of drugs that has occurred here recently, we are hoping to enter the market by using a wide range of your globally renowned products. We would like to send you a list of your products which we are interested in dealing with, and would appreciate it greatly if you could supply us with the price list for them. We hope that you may agree to this offer, and hope to receive a reply from you as soon as possible. May this be the beginning of a successful business relationship between us, for we are truly looking forward to working in cooperation with your company... All our best regards to you To whom it may concern

We are a distributer of drugs & medical supplies, working in one of the main hospitals here in Libya.
After the huge expansion in the marketing of drugs that has occurred here recently, we are hoping to enter the market by using a wide range of your globally renowned products.
We would like to send you a list of your products which we are interested in dealing with, and would appreciate it greatly if you could supply us with the price list for them.
We hope that you may agree to this offer, and hope to receive a reply from you as soon as possible.
May this be the beginning of a successful business relationship between us, for we are truly looking forward to working in cooperation with your company…

All our best regards to you

]]> By: Rethinking a Schering-Plough turnaround :: OnThePharm http://onthepharm.net/2006/06/schering-ploug-turnaround.html#comment-236 Rethinking a Schering-Plough turnaround :: OnThePharm Wed, 02 Aug 2006 16:41:26 +0000 http://onthepharm.net/2006/06/schering-ploug-turnaround/#comment-236 [...] A month ago to the day, I mentioned Schering-Plough in a negative light. I said that the company wasn’t going to do well, but I’m beginning to re-think my original thoughts, after hearing more about CEO Fred Hassan. It’s always fun to hate on CEOs — they take the blame for everything, sort of the like the POTUS — even if something isn’t necessarily their fault. They inherit the deficiencies of the companies they run when they takeover. [...] [...] A month ago to the day, I mentioned Schering-Plough in a negative light. I said that the company wasn't going to do well, but I'm beginning to re-think my original thoughts, after hearing more about CEO Fred Hassan. It's always fun to hate on CEOs — they take the blame for everything, sort of the like the POTUS — even if something isn't necessarily their fault. They inherit the deficiencies of the companies they run when they takeover. [...]

]]> By: OnThePharm » “Pill Pushers” — science for salesmanship? http://onthepharm.net/2006/06/schering-ploug-turnaround.html#comment-26 OnThePharm » “Pill Pushers” — science for salesmanship? Sun, 04 Jun 2006 03:10:34 +0000 http://onthepharm.net/2006/06/schering-ploug-turnaround/#comment-26 [...] There needs to be a balance between short-term profits and long term value. This is a balance that I haven’t seen Big Pharma strike, yet. Eventually they will, because their long-term survival will depend on it. No analyst is going to give good ratings to a company with a dry pipeline. Schering-Plough lost two thirds of its market cap in the last several years for this reason. Beating the horse for that last burst isn’t going to matter when you try to begin the next lap and it dies under you. You need fresh products to perpetuate your survival. And the pharmaceutical industry hasn’t figured out the right balance yet. Just like the technology industry, the savior of Big Pharma will likely be licensing agreements with and acquisitions of smaller biotech companies that have developed new therapies. Smaller companies can innovate and change faster than large ones can, but they lack the massive infrustracture (marketing, manufacturing, etc.) that large companies can bring to the table. [...] [...] There needs to be a balance between short-term profits and long term value. This is a balance that I haven't seen Big Pharma strike, yet. Eventually they will, because their long-term survival will depend on it. No analyst is going to give good ratings to a company with a dry pipeline. Schering-Plough lost two thirds of its market cap in the last several years for this reason. Beating the horse for that last burst isn't going to matter when you try to begin the next lap and it dies under you. You need fresh products to perpetuate your survival. And the pharmaceutical industry hasn't figured out the right balance yet. Just like the technology industry, the savior of Big Pharma will likely be licensing agreements with and acquisitions of smaller biotech companies that have developed new therapies. Smaller companies can innovate and change faster than large ones can, but they lack the massive infrustracture (marketing, manufacturing, etc.) that large companies can bring to the table. [...]

]]>